

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10510064	
	Filing Date		2002-04-04	
	First Named Inventor	Kamalakar Talasila		
	Art Unit			
	Examiner Name			
Attorney Docket Number		GEN 3.3-015		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3878217		1975-04-15	Carr, et al.	
	2	4996061		1991-02-26	Webb, et al.	
	3	6039974		2000-03-21	MacLaren, et al.	
	4	6267986	B1	2001-07-31	Jain, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10510064
Filing Date		2002-04-04
First Named Inventor	Kamalakar Talasila	
Art Unit		
Examiner Name		
Attorney Docket Number	GEN 3.3-015	

1	99/09957	WO	A1	1999-03-04	HOECHST MARION ROUSSEL, INC.	<input type="checkbox"/>
2	01/85148	WO	A2	2001-11-15	AVENTIS PHARMACEUTICALS, INC.	<input type="checkbox"/>
3	01/94313	WO	A2	2001-12-13	NOVARTIS AG	<input type="checkbox"/>
4	02/080857	WO	A2	2002-10-17	TEVA PHARMACEUTICAL INDUSTRIES LTD. -	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	SIMPSON, K., ET AL., "Fexofenadine a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria", Journal of Allergy and Clinical Immunology, Vol. 2, No. 59, pages 301-321, 2000.	<input type="checkbox"/>
	2	SUSSMAN, G.L., ET AL., "The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis", Journal of Allergy and Clinical Immunology, Vol. 104, No. 1, pages 100-106, 1999.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.